eISSN: 2299-0046
ISSN: 1642-395X
Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii
Current issue Archive Manuscripts accepted About the journal Editorial board Reviewers Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures
Editorial System
Submit your Manuscript
SCImago Journal & Country Rank
Search
Editorial Policies
Sarajevo Declaration on Integrity and Visibility of Scholarly Publications
Share:
Send email
Share:
Original paper

The effects of montelukast sodium in conjunction with budesonide/formoterol on pulmonary function and serum markers (interleukin-6, tumor necrosis factor-a, eosinophils (EOS) count) in obstructive airway diseases (asthma and chronic obstructive pulmonary disease)

Zhen Wang
1
,
Wei Zhang
1
,
Weifang Xu
2

  1. Department of Pulmonary Disease, Guangzhou University of Traditional Chinese Medicine Shenzhen Hospital (Futian), ShenZhen, China
  2. Respiratory and Critical Care Medicine, Guangzhou University of Traditional Chinese Medicine Shenzhen Hospital (Futian), ShenZhen, China
Adv Dermatol Allergol
DOI: https://doi.org/10.5114/ada.2024.144825
Online publish date: 2024/11/08
Article file
- The effects - Wang.pdf  [0.15 MB]
Get citation
 
 
1. Lareau SC, Fahy B, Meek P, et al. Chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med 2019; 199: 1-2.
2. Christenson SA, Smith BM, Bafadhel M, et al. Chronic obstructive pulmonary disease. Lancet 2022; 399: 2227-42.
3. Yang IA, Jenkins CR, Salvi SS. Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and implications for prevention and treatment. Lancet Respir Med 2022; 10: 497-511.
4. Agustí A, Vogelmeier C, Faner R. COPD 2020: changes and challenges. Am J Physiol Lung Cell Mol Physiol 2020; 319: L879-83.
5. Mümmler C, Milger-Kneidinger K. COPD-exacerbation: therapeutic consequences. MMW Fortschr Med 2020; 162: 46-9.
6. Terry PD, Dhand R. Inhalation therapy for stable COPD: 20 years of GOLD reports. Adv Ther 2020; 37: 1812-28.
7. Mera-Cordero F, Bonet-Monne S, Almeda-Ortega J, et al. Double-blind placebo-controlled randomized clinical trial to assess the efficacy of montelukast in mild to moderate respiratory symptoms of patients with long COVID: E-SPERANZA COVID Project study protocol. Trials 2022; 23: 19.
8. Shang N, Liu Y, Jin Y. Comparative efficacy of budesonide/formoterol versus fluticasone/salmeterol in patients with moderate-to-severe chronic obstructive pulmonary disease: a systematic review and meta-analysis. COPD 2024, 21: 2328708.
9. Jiang T, Li P, Wang Y. Effect of budesonide formoterol combined with tiotropium bromide on pulmonary function and inflammatory factors in patients with asthma-COPD overlap syndrome. Allergol Immunopathol (Madr) 2023; 51: 131-8.
10. Kaya-Yasar Y, Engin S, Barut EN, et al. The contribution of the WNT pathway to the therapeutic effects of montelukast in experimental murine airway inflammation induced by ovalbumin and lipopolysaccharide. Drug Dev Res 2024; 85: e22178.
11. Marques CF, Marques MM, Justino GC. Leukotrienes vs. montelukast-activity, metabolism, and toxicity hints for repurposing. Pharmaceuticals (Basel) 2022; 15: 1039.
12. Lipworth B, Kuo CR, Stewart K, et al. Budesonide/formoterol or budesonide/albuterol as anti-inflammatory reliever therapy for asthma. J Allergy Clin Immunol Pract 2024; 12: 889-93.
13. Hon KL, Leung TF, Leung AK. Clinical effectiveness and safety of montelukast in asthma. What are the conclusions from clinical trials and meta-analyses?. Drug Design Develop Ther 2014: 839-50.
14. Wei Z, Li S. An efficacy and safety evaluation of montelukast + fluticasone propionate vs. fluticasone propionate in the treatment of cough variant asthma in children: a meta-analysis. BMC Pulm Med 2023; 23: 489.
15. Xu Q, Lu T, Song Z, et al. Efficacy and safety of montelukast adjuvant therapy in adults with cough variant asthma: a systematic review and meta‐analysis. Clin Respir J 2023; 17: 986-97.
16. Song Z, Meng Y, Fricker M, et al. The role of gut-lung axis in COPD: pathogenesis, immune response, and prospective treatment. Heliyon 2024; 10: e30612.
17. Zheng D, Liu X, Zeng W, et al. Association of hepatic steatosis and liver fibrosis with chronic obstructive pulmonary disease among adults. Sci Rep 2024; 14: 10822.
18. Zhao Y, Wu Z. TROP2 promotes PINK1-mediated mitophagy and apoptosis to accelerate the progression of senile chronic obstructive pulmonary disease by up-regulating DRP1 expression. Exp Gerontol 2024; 191: 112441.
19. Dai X, Feng T, Zhang X, Li K. Budesonide/fomoterol in combination with montelukast in the treatment of bronchial asthma. Pakistan J Med Sci 2020; 36: 1688.
20. Chen Z, Qian X. Effect of montelukast/budesonide formoterol powder inhalation in chronic obstructive pulmonary disease. Trop J Pharm Res 2022; 21: 1037-43.
21. Yi F, Zhan C, Liu B, et al. Effects of treatment with montelukast alone, budesonide/formoterol alone and a combination of both in cough-variant asthma. Respir Res 2022; 23: 279.
22. Esnault S, Khosravi M, Kelly EA, et al. Increased IL‐6 and Potential IL-6 trans-signalling in the airways after an allergen challenge. Clin Exp Allergy 2021; 51: 564-73.
Copyright: © 2024 Termedia Sp. z o. o. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (http://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
FEATURED PRODUCTS
BOOKS
• Atopowe Zapalenie Skóry • Choroby alergiczne w praktyce lekarza rodzinnego • Alergologia – kompendium
Termedia
About us Contact
Copyright notice Privacy policy Advertising policy Contact us
Quick links
Journals Books eBooks Events
© 2024 Termedia Sp. z o.o.
Developed by Bentus.